Sorbent-based artificial liver devices: Principles of operation, chemical effects and clinical results

Expert Review of Medical Devices

Volumn 4, Issue 6, 2007, Pages 839-861

  Carpentier, Benoît ^a   Ash, Stephen R ^b  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b Clarian Arnett Health   (United States)

Author keywords

Artificial liver; Bioartificial liver; Charcoal; Liver failure; Liver support; Resins; Sorbents

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ANTIBIOTIC AGENT; BILIRUBIN; FRESH FROZEN PLASMA; HEPARIN; LACTULOSE; PARACETAMOL; PROSTACYCLIN; PROTAMINE;

ALCOHOL LIVER DISEASE; ARTIFICIAL LIVER; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD FILTRATION; BRAIN EDEMA; CARDIOGENIC SHOCK; CHOLECYSTITIS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG OVERDOSE; GRAFT DYSFUNCTION; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOPERFUSION; HEPATIC ENCEPHALOPATHY; HEPATITIS A; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; INFECTION; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; LIVER SUPPORT; LIVER TOXICITY; LIVER TRANSPLANTATION; MACROMOLECULE; METHODOLOGY; NEUROLOGIC DISEASE; NUTRIENT SUPPLY; OUTCOME ASSESSMENT; PRURITUS; REVIEW; SCLEROTHERAPY; SURVIVAL RATE; TREATMENT DURATION;

CLINICAL TRIALS AS TOPIC; DIALYSIS; HEMODYNAMICS; HUMANS; LIVER, ARTIFICIAL; SORPTION DETOXIFICATION;

EID: 37649013605     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.4.6.839     Document Type: Review

References (73)

1. Tan HK. Molecular Adsorbent Recirculating System (MARS), review article. Ann. Acad. Med. Singapore 33, 329-335 (2004).
2. Zhou XM, Miao JY, Yang Y et al. Clinical experience with Molecular Adsorbent Recirculating System (MARS) in patients with drug-induced liver failure. International Center for Artificial Organs and Transplantation 28(5), 483-486 (2004).
3. Holt AW. Acute liver failure. Crit. Care Resusc. 1. 25-38 (1999).
4. Keeffe EB. Acute liver failure, Rev. Gastroenterol. Mex. 70(1), 56-62 (2005).
5. Lee WM. Acetaminophen and the US acute liver failure study group: lowering the risks of hepatic failure. Hepatology 40(1), 6-9 (2004).
6. Larson AM, Poison J. Fontana RJ et al. Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter. prospective study. Hepatology 42(6), 1364-1372 (2005).
7. Stange J, Mitzner SR, Klammt S. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl. 6, 603-613 (2000).
8. Zaman MB. Hoti E, Qasim A et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant. Proc. 38(7), 2097-2098 (2006).
9. Chan HL, Chim AM, Lau JT et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am. J. Gastroenterol. 101(7), 1516-1523 (2006).
10. Yoshiba M, Sekiyama K, Iwamura Y et al. Development of reliable artificial liver support (ALS) plasma exchange in combination with hemodiafiltration using high-performance membrane. Dig. Dis. Sci. 38, 469-476 (1993).
11. Matsubara S, Okabe K, Ouchi K et al. Continuous removal of middle molecules by hemofiltration in patient with acute liver failure. Crit. Care Med. 18, 1331-1338 (1990).
12. Krisper P, Haditsch B, Stauber R et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J. Hepatol. 43, 451-457 (2005).
13. Rozga J. Liver support technology - an update. Xenotransplantation 13(5), 380-389. (2006).
14. Inderbitzin, D, Muggli B, Ringger A et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J. Gastrointest. Surg. 9, 1155-1162 (2005).
15. Koivusalo AM, Vakkuri A, Höckerstedt K et al. Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant. Proc. 37, 3315-3317 (2005).
16. O'Grady JG, Gimson AE, O'Brien CJ et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94(5 Pt 1), 1186-1192 (1988).
17. Aladag M, Gurakar A, Jalil S et al. A liver transplant center experience with liver dialysis in the management of patients with fulminant hepatic failure: a preliminary report. Transplant. Proc. 36, 203-205 (2004).
18. Novelli G, Rossi M. Pretagostini M et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant. Proc. 37, 2557-2559 (2005).
19. Jalan R. Sen S, Steiner C et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J. Hepatol. 38, 24-31 (2003).
20. National Horizon Scanning Center. New and emerging technology briefing: Molecular Adsorbent Recirculating System (MARS) for the treatment of acute and acute on chronic liver failure. Horizon Scanning Review (2003).
21. El Banayosy A, Kizner L, Schueier V et al. The role of MARS in patients suffering from hypoxic liver failure secondary to cardiogenic shock. ITBM-RPM 23(Suppl. I) 61-66 (2002).
22. Acevedo Rim M, Moreno Planas JM, Sanz Moreno C et al. Therapy of intractable pruritus with MARS. Transplant. Proc. 37, 1480-1481 (2005).
23. Sen S, Mookerjee RP, Cheshire LM et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J. Hepatol. 43, 142-148 (2005).
24. Sen S, Williams R, Jalan R, Emerging indication for albumin dialysis. Am. J. Gastroenterol. 100, 468-475 (2005).
25. Lee K-H, Lee MK-H, Sutedja DS et al. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver International 25, 973-977 (2005).
26. Novelli G, Rossi M, Ferretti G et al. Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma. Transplant. Proc. 37, 2560-2562.(2005).
27. Rifai K, Ernst T, Kretschmer U et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J. Hepatol. 39, 984-990 (2003).
28. Skwarek A, Grodzicki M, Nyckowski P et al. The use of prometheus FPSA, System in the treatment of acute liver failure: preliminary results. Transplant. Proc. 38, 209-211 (2006).
29. Rifai K, Ernst T. Kretschmer U et al. Removal selectivity of Prometheus: A new extracorporeal liver support device. World J. Gastroenterol. 12(6), 940-944 (2006).
30. Ash S, Extracorporeal Blood Detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace. Ther. 9(1), pp 3-18 (2002).
31. Ash S, Steczko J, Levy H et al. Treatment of systemic Inflammatory response syndrome by push-pull powdered sorbent pheresis: a Phase 1 clinical trial. Ther Apher. 5(6). 497-505 (2001).
32. Ash SR, Carr DJ. Characterizing activated carbon for sorbent therapy. ASAIO J. 52(2), P11A (2006).
33. Patzer JF 2nd, Bane SE. Bound solute dialysis. ASAIO J. 49(3), 271-281 (2003)
34. Ash SR, Blake DE, Carr DJ et al. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int. J. Artif Organs 15, 151 (1992).
35. Ash SR. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs. 18, 355 (1994).
36. Ash SR, Blake DE, Carr DJ et al. Neurologic improvement of patients with hepatic failure and coma during sorbent suspension dialysis. ASAIO Trans. 37, M332 (1991).
37. Ash SR. Powdered sorbent liver dialysis and pheresis in treatment of hepatic failure. Ther. Apher. 5(5), 404-416 (2001).
38. Wilkinson AH, Ash SR, Nissenson AR. Hemodiabsorption in treatment of hepatic failure [published erratum appears in J. Transpl. Coord. 8(2), 73 (1998)]. J. Transpl, Coord. 8, 43 (1998).
39. Kramer L, Gendo A, Madi C et al. A controlled study of the BioLogIc-DT System in chronic hepatic encephalopathy (abstract). Hepatology. 28, 410A (1998).
40. Ellis AJ, Hughes RD, Nicholl D et al. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Int. J. Artif. Organs 22. 27-34 (1999).
41. Kjaergard LL, Liu J, Als-Nielsen B et al. Artificial and bioartificial support systems: for acute and acute-on-chronic liver failure. JAMA 289(2), 217-222 (2003).
42. Hill K. Hu KQ, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am. J. Gastroenterol. (12), 2763-2770 (2003).
43. Huang KW, Chao A, Chou NK, Ko WJ. Hepatic encephalopathy and cerebral blood flow improved by liver dialysis treatment. Int. J. Artif. Organs 26(2): 149-151 (2003).
44. Winchester JF. Active methods of detoxification. In: Clinical Management of Poisoning and Drug Overdose. Haddad LM, Winchester JF (Eds). Saunders, PA, USA, 148 (1990).
45. Schiodt FV, Rochling FA, Casey DI et al. Acetaminophen toxicity in an urban county hospital. N. Engl. J. Med. 337, 1112 (1997).
46. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 346, 547 (1995).
47. Smilkstein MJ, Knapp GL, Kulig KW et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Eng. J. Med. 319, 1557-1562 (1988).
48. Ash SR, Caldwell CA, Singer GG et al. Treatment of aceteminophen-induced hepatitis and fulminant hepatic failure by the BioLogic-DT system (abstract). Hepatology 30, 552A (1999).
49. Rumack BH, Peterson RG, Koch GG et al. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. Azch. Intern. Med. 141, 380-385 (1981).
50. Williams R, Langley PG, Pereira SP. The management of abnormalities of hemostasis in acute liver failure. Semin. Liver Dis. 16, 403 (1996).
51. Violi F, Ferro D, Basili S et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 109, 531 (1995).
52. Kramer L, Gendo A, Madi C et al. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am. J. Kidney Dis. 36(6), 1193 (2000).
53. Hillebrand DJ, Hill KB, Hu KQ et al. Formal heparin anticoagulation protocol improves safety of charcoal-based liver assist treatments. ASAIO J. 52(3), 334-342 (2006).
54. Stefoni S, Coli L, Bolondi L et al. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int. J. Artif. Organs 29(2), 207-218 (2006).
55. Schmidt LE, Svendsen LB, Sorensen VR et al. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbent recirculating system in patients with acute-on-chronic liver failure. Liver Transplant. 7, 709-712 (2001).
56. Sorkine P, Ben Habraham R, Szold O et al. Role of the molecular adsorbent recirculating system (MARS) in patients with acute exacerbation of chronic liver failure. Crit. Care Med. 29, 1332-1336 (2001).
57. Abraham RB, Szold O, Merhav P. Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant. Proc. 33, 2897-2899 (2001).
58. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the international MARS registry. Liver 22, 20-25 (2002).
59. Stange J, Mitzner SR, Risler T. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif. Organs. 23, 319-330 (1999).
60. Mullhaupt B, Kullak-Ublick GA, Ambuhl P. First clinical experience with molecular adsorbent recirculating system (MARS) in six patients with severe acute on chronic liver failure. Liver 22, 59-62 (2002).
61. Wilmer A, Nevens F, Evenepoel P. The molecular adsorbent recirculating system in patients with severe liver failure: clinical results at the K.U. Leuven. Liver 22, 52-55 (2002).
62. Novelli G, Rossi M, Pretagostini R. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant. Proc. 33, 1942-1944 (2001).
63. Heemann U, Treichel U, Loock J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36, 949-958 (2002).
64. Mitzner SR, Strange J, Klammt S, Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomised, controlled clinical trial. Liver Transpl. 6, 277-286 (2000).
65. Kellersmann R, Gassel HJ, Buhler C. Application of molecular adsorbent recirculating system to patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver 22, 56-58 (2002).
66. Stange J, Hassanein TI, Mehta R et al. The molecular adsorbent recycling system as a liver support system based on albumin dialysis: a summary of preclinical experience from 19 centers. Artif. Organs. 26, 103-110 (2002).
67. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann. Intern. Med. 131, 47-59 (1999).
68. Birgens HS, Henriksen J, Matzen PH, Poulsen, The shock liver. Clinical and biochemical findings in patients with centrilobular liver necrosis following cardiogenic shock. Acta Med. Scand. 204(5), 417-421 (1978).
69. Evenepoel P, Laleman W, Wilmer A et al. Detoxifying capacity and kinetics of Prometheus - a new extracorporeal system for the treatment of liver failure. Blood Purif. 23, 349-358 (2005).
70. Rifai K, Ernst T, Kretschmer U et al. The prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif. 23, 298-302 (2005).
71. Karvellas CJ, Gibney N, Kutsogiannis D, Wendon J, Bain VG. Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit. Care 11(3), 215. (2007).
72. Santoro A, Mancini E, Ferramosca E, Faenza S. Liver support systems. Contrib. Nephrol. 156, 396-404 (2007).
73. Krisper P, Stauber RE. Technology insight: artificial extracorporeal liver support - how does Prometheus compare with MARS? Nat. Clin. Pract. Nephrol. 3(5), 267-276 (2007).